Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,680 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antibody-based therapy for solid tumors.
Yan L, Hsu K, Beckman RA. Yan L, et al. Cancer J. 2008 May-Jun;14(3):178-83. doi: 10.1097/PPO.0b013e318172d71a. Cancer J. 2008. PMID: 18536557 Review.
How can we improve antibody-based cancer therapy?
Yan L, Ehrlich PJ, Gibson R, Pickett C, Beckman RA. Yan L, et al. MAbs. 2009 Jan-Feb;1(1):67-70. doi: 10.4161/mabs.1.1.7359. MAbs. 2009. PMID: 20046576 Free PMC article.
Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers.
Yap TA, Yan L, Patnaik A, Tunariu N, Biondo A, Fearen I, Papadopoulos KP, Olmos D, Baird R, Delgado L, Tetteh E, Beckman RA, Lupinacci L, Riisnaes R, Decordova S, Heaton SP, Swales K, deSouza NM, Leach MO, Garrett MD, Sullivan DM, de Bono JS, Tolcher AW. Yap TA, et al. Among authors: yan l. Clin Cancer Res. 2014 Nov 15;20(22):5672-85. doi: 10.1158/1078-0432.CCR-14-0868. Epub 2014 Sep 19. Clin Cancer Res. 2014. PMID: 25239610 Free PMC article. Clinical Trial.
Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial.
Moran T, Felip E, Keedy V, Borghaei H, Shepherd FA, Insa A, Brown H, Fitzgerald T, Sathyanarayanan S, Reilly JF, Mauro D, Hsu K, Yan L, Johnson DH. Moran T, et al. Among authors: yan l. Exp Hematol Oncol. 2014 Nov 7;3(1):26. doi: 10.1186/2162-3619-3-26. eCollection 2014. Exp Hematol Oncol. 2014. PMID: 25414803 Free PMC article.
Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors.
Tolcher AW, Kurzrock R, Valero V, Gonzalez R, Heist RS, Tan AR, Means-Powell J, Werner TL, Becerra C, Wang C, Leonowens C, Kalyana-Sundaram S, Kleha JF, Gauvin J, D'Amelio AM Jr, Ellis C, Ibrahim N, Yan L. Tolcher AW, et al. Among authors: yan l. Cancer Chemother Pharmacol. 2020 Apr;85(4):673-683. doi: 10.1007/s00280-020-04038-8. Epub 2020 Feb 15. Cancer Chemother Pharmacol. 2020. PMID: 32062691 Free article. Clinical Trial.
Anti-EMMPRIN monoclonal antibody as a novel agent for therapy of head and neck cancer.
Dean NR, Newman JR, Helman EE, Zhang W, Safavy S, Weeks DM, Cunningham M, Snyder LA, Tang Y, Yan L, McNally LR, Buchsbaum DJ, Rosenthal EL. Dean NR, et al. Among authors: yan l. Clin Cancer Res. 2009 Jun 15;15(12):4058-65. doi: 10.1158/1078-0432.CCR-09-0212. Epub 2009 Jun 9. Clin Cancer Res. 2009. PMID: 19509148 Free PMC article.
12,680 results
You have reached the last available page of results. Please see the User Guide for more information.